Milan – October 02, 2026 -- Hansoh Pharma's dual-biased GLP-1/GIP receptor agonist Olatorepatide (HS-20094) achieved a mean weight loss of 19.3% at Week 48 in the 15 mg dose group of a Phase III Chinese trial, with no plateau observed in the weight-loss curve.
The data, presented as a Late-breaking Abstract oral presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting running September 28 to October 2, 2026 in Milan, come from the LIGHTEN study, a multicenter, randomized, double-blind, placebo-controlled trial enrolling 604 Chinese adults with overweight or obesity.
Trial enrolled 604 participants across four dose arms over 48 weeks
Participants with a BMI of 28 kg/m2 or above, or 24-28 kg/m2 with a weight-related comorbidity, were randomized 1:1:1:1 to once-weekly subcutaneous Olatorepatide at 5mg, 10mg or 15mg, or placebo. A total of 90.1% completed the full 48-week treatment period.
Higher doses drove body weight reductions of up to 19.3% versus 2.7% for placebo
Under the efficacy estimand, mean body weight reductions at Week 48 were -12.5%, -17.5% and -19.3% for the 5mg, 10mg and 15mg groups respectively, compared with -2.7% for placebo (P 0.0001 for all comparisons). Under the treatment-regimen estimand, reductions were -11.8%, -17.0% and -18.7% versus -2.5% for placebo.
Up to 71.7% of patients on 15mg dose lost at least 15% of body weight
Weight-loss goal achievement rates under the efficacy estimand showed 95.2% of the 15mg group achieved at least 5% weight loss, 88.9% achieved at least 10%, and 71.7% achieved at least 15%, against placebo rates of 28.6%, 14.6% and 3.2% respectively. The 10mg group recorded the highest ≥5% response rate at 97.2%.
Waist circumference dropped 16.0 cm in the highest-dose group
Mean waist-circumference reduction reached 16.0 cm in the 15mg group, versus 3.6 cm for placebo (P 0.0001). The drug also improved blood pressure, lipid profiles, HbA1c, HOMA-IR, urine albumin-to-creatinine ratio and uric acid levels.
Gastrointestinal adverse events remained below rates reported for existing incretin therapies
Mean incidence of nausea and vomiting across Olatorepatide treatment groups was 7.8% and 4.9% respectively, against 2.6% and 2.0% for placebo. Diarrhea occurred in 16.9% of treated participants versus 7.8% on placebo, and constipation in 5.1% versus 1.3%. No participants discontinued or withdrew early due to treatment-related adverse events.
NMPA accepted the weight management NDA in June 2026 following Regeneron licensing deal
China's National Medical Products Administration accepted the New Drug Application for Olatorepatide for long-term weight management in June 2026. Olatorepatide is also in Phase III development in China for type 2 diabetes. In June 2025, Hansoh Pharmaceutical granted Regeneron exclusive overseas development and commercialization rights for the asset.